Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.
about
Challenges in mucosal HIV vaccine development: lessons from non-human primate modelsMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsSurvivors Remorse: antibody-mediated protection against HIV-1.Is there a role for plant-made vaccines in the prevention of HIV/AIDS?High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challengeMucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantReplicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.IIIa deleted adenovirus as a single-cycle genome replicating vector.Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyCurrent progress in the development of a prophylactic vaccine for HIV-1.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaquesVaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Non-human primate models for AIDS vaccine research.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesStrong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusEfficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsPriming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheCTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.A call for replicating vector prime-protein boost strategies in HIV vaccine design.
P2860
Q27022152-1ED39508-11F7-4257-AF67-02317EF99D66Q27318151-7348EEFB-66FD-4B16-93F7-87B6F4C042B4Q28732043-254C3627-5C42-4217-9923-CDC046399909Q30238730-71EBCB6C-BD76-494A-B7E1-28329C024AF8Q30350670-2E2D9F49-3920-4B91-989F-66F8B7FC59B1Q30354064-A4392BD6-3361-482F-8FBD-804C24A6E587Q30375160-FE6701C4-B3B6-4721-AEDA-9F21999687E3Q33565035-1685F5CF-8E62-4FB0-B7AE-59D16824F52CQ33843258-4C7C57E2-797C-4790-A7FD-6ECF6BE2F74CQ33843297-0411E79D-D1FA-450E-B3F7-E483A057BB10Q33872445-1D8F32CD-14B3-49EF-8882-4036099B3059Q33877513-7DD06E91-A813-4A2A-8236-FC630B8D382DQ33911986-ECEBD6AE-E3FA-4E18-B679-68F9E9DF8C81Q33932258-1F3C3D70-1D7F-43A3-8779-EADA87F753CAQ33966586-26482FBD-B31E-403F-B74C-09D16069F0DEQ33984182-38336518-2432-4AE8-8EF9-29B219877F35Q34006329-E34395BE-FAFD-4E03-9AF0-7B928E6D8FAFQ34016756-2E4658D6-98E9-4917-BB4C-FFB11287CF37Q34485178-769F235C-2FCE-4C78-875E-685CA33705A2Q34502108-94D69780-7482-4110-9D74-F82C5CFC04CFQ34540352-ABBF482F-4B9E-44DC-B8CA-081783EAFC52Q34574409-AC4AA7C4-C878-4803-89D6-C5CCCF145C95Q34616275-FFC0DE49-54D8-4BAC-99D1-D47628135602Q34651604-B4A3F372-82D6-4076-8067-FE0A3184B479Q34715769-CB57364B-5366-4ECA-A86A-F322A07FE106Q34781602-842FBB28-3359-4706-B7B2-5F2554A057A0Q34810713-624D76E1-F1A7-4944-8870-DD7E5AFD7200Q35021632-0EBF264A-066B-4602-B0ED-F69FE3216B07Q35024276-87CB8AD5-9CD2-4966-BD73-995A36A202E3Q35032794-68F0F5CD-ABA0-488E-A62D-B7799FCF8F29Q35141486-E0A329E7-D6ED-47CE-B663-0EE7D51FB766Q35156935-C088D065-A177-4D8B-A7F9-094CA3791B73Q35636394-8F96BF78-B772-4FD7-8D2C-498B81A91FBAQ35672335-FD89EDCB-09A3-427E-8910-672C33AEAB5DQ35675044-7489EA87-55E6-4427-9943-093EC7DE59AEQ35677724-FA50B76F-8A20-403C-AB55-9C81452EAE65Q35784197-50B72863-2BC3-4257-8341-578D3DD5DD8CQ35785031-C7122775-A0A8-416E-AFE5-F00993E43337Q35848881-DDDCE8E1-5223-4152-8761-121D60E691CBQ35851801-D57B6D43-C36D-4882-83FD-495170925457
P2860
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Protection against mucosal sim ...... priming and subunit boosting.
@en
type
label
Protection against mucosal sim ...... priming and subunit boosting.
@en
prefLabel
Protection against mucosal sim ...... priming and subunit boosting.
@en
P2093
P2860
P1433
P1476
Protection against mucosal sim ...... priming and subunit boosting.
@en
P2093
David Venzon
Frank A Robey
Joel Pinczewski
L Jean Patterson
Liqun Wang
Marjorie Robert-Guroff
Nina Malkevitch
Phillip D Markham
V S Kalyanaraman
Victor Raúl Gómez-Román
P2860
P304
P356
10.1128/JVI.78.5.2212-2221.2004
P407
P577
2004-03-01T00:00:00Z